A recent study suggests that people who stop using blockbuster slimming jabs like Mounjaro or Wegovy can put back on lost weight much more quickly than those who end conventional lifestyle programs.
Findings released in a leading medical journal demonstrates that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Users purchasing these treatments must be cognizant of the danger of quick rebound weight gain when the medication concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain means a return to pre-treatment mass in about a year and a half.
Analyzing Approaches
The research, which reviewed 37 of trials involving over 9,000 of participants, compared the outcomes of these new drugs with older methods.
Researchers point out that individuals who lose weight through diet and exercise usually experience a less rapid creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Nutrition scientists suggest the way of the injections explains the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of the hormone concentrations far above than normal could lead to the body to produce less of its own natural hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement means hunger is no longer kept in check, making overeating much more probable."
A Chronic Disease?
Health authorities suggest the jabs for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, given the likelihood of weight regain, the therapy is often life-long.
This perspective is reinforced by drug manufacturers, who note that the results "highlight the chronic character of obesity," similar to managing diseases like diabetes.
User Experiences
Individuals who have discontinued the jabs report a powerful resurgence of appetite.
"It felt as if a switch flipping and I was suddenly starving," recalled one woman.
This challenge is exacerbated if patients have not adopted sustainable lifestyle or habit modifications during therapy.
Widespread Use
Recent estimates indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is greater among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
Finally, researchers emphasize that while the jabs are effective tools for weight loss, they are not a magic fix and long-term success relies on combined behavioural support.
